| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00244920 Details | 2012-05-28 Interventional | 2 | 0 | Androgen Antago… Bicalutamide Hormones Leuprolide Squalamine Prostatic Neopl… Prostate Cancer | Sponsor withdrew drug. - | |||
| NCT00243009 Details | 2012-05-28 Interventional | 2 | 1 | Cyclosporine Cyclosporins Fludarabine Fludarabine pho… Mycophenolic Ac… Carcinoma, Rena… Kidney Neoplasm… Kidney Cancer | Due to a lack of a referal base, study was terminated. - | |||
| NCT00240747 Details | 2012-05-25 Interventional | 3 | - | Quinupristin-da… Bacterial Infec… Gram-Positive B… | - - | |||
| NCT00006269 Details | 2012-05-25 Interventional | 3 | 89 | Irinotecan Octreotide Colorectal Neop… Diarrhea Colorectal Canc… | - - | |||
| NCT00249899 2005-004876-19 Details | 2012-05-24 Interventional | 3 | [1 Refs] | 649 | Atorvastatin Hydroxymethylgl… Rosuvastatin Ca… Simvastatin Hypercholestero… | Overall profile of the compound does not offer significant clinical advantage to patients over
currently available lipid lowering agents - | ||
| NCT00237575 Details | 2012-05-23 Interventional | 3 | - | Gemcitabine Sargramostim Urinary Bladder… Bladder Cancer | - - | |||
| NCT00073970 Details | 2012-05-23 Interventional | 2 | 37 | Celecoxib Prostatic Neopl… Prostate Cancer | Study stopped due to increased cardiovascular risks associated with Celebrex - | |||
| NCT00042315 Details | 2012-05-23 Interventional | 3 | - | Vinorelbine Carcinoma, Non-… Lung Neoplasms Stage IIIb Non-… Stage IV Non-sm… | - - | |||
| NCT00042302 Details | 2012-05-23 Interventional | 3 | - | Albumin-Bound P… Carboplatin Paclitaxel Carcinoma, Non-… Lung Neoplasms Stage IIIb Non-… Stage IV Non-sm… | - - | |||
| NCT01124656 Details | 2012-05-21 Interventional | 3 | 26 | Azilsartan medo… Pioglitazone Diabetes Mellit… Diabetes Mellit… | Formulation issues. - | |||
| NCT00763347 Details | 2012-05-21 Interventional | 2 | 82 | Alogliptin Diabetes Mellit… | Voluntarily terminated based on preliminary non-clinical findings. - | |||
| NCT01601899 Details | 2012-05-18 Interventional | 4 | 60 | Efavirenz Lamivudine Stavudine Tenofovir Metabolic Compl… Mitochondrial T… | DSMB decision to begin closeout process in view of April 2010 SA HAART guideline - | |||
| NCT00807209 Details | 2012-05-15 Interventional | 2 | 3 | Bupivacaine Fentanyl Pain, Postopera… Postoperative P… | Sponsor decision unrelated to safety The study was terminated early due to Sponsor's decision, unrelated to safety. As there was only one patient in each group, no efficacy analyses were performed. | |||
| NCT00932464 Details | 2012-05-14 Interventional | 1 | 0 | Neratinib Healthy | Study withdrawn as it no longer is deemed necessary per project status. - | |||
| NCT00312546 Details | 2012-05-14 Interventional | 1 | 14 | Enfuvirtide Valproic Acid HIV Infections | - - | |||
| NCT00251511 Details | 2012-05-11 Interventional | 2 | 60 | Arsenic Trioxid… Myelodysplastic… Preleukemia Syndrome Myelodysplastic… | Sponsor terminated trial - | |||
| NCT01050491 Details | 2012-05-10 Interventional | 2 | 17 | Sitaxsentan Airway Remodeli… Asthma Effect of Sitax… | sitaxentan is not commercialized anymore - | |||
| NCT00876850 Details | 2012-05-09 Interventional | 3 | 0 | Linezolid Communicable Di… Infections Skin Diseases, … Soft Tissue Inf… Skin Structures… | Terminated - | |||
| NCT01103193 Details | 2012-05-08 Interventional | 4 | 4 | Remifentanil Sevoflurane ASA Class I/II … | Need of change to the protocol. As the Principal Investigator has left the University Hospital
Ghent end 2010, the change of protocol was never submitted. - | |||
| NCT00449813 Details | 2012-05-07 Interventional | 4 | 40 | Pantoprazole Gastroesophagea… Non-Erosive Ref… Gastroesophagea… Non-erosive Ref… | Inclusion-rate does not seem feasible anymore to obtain te required number of patients before
the end of the trial. - |